Abbott receives fda clearance for assert-iq™ insertable cardiac monitor to help doctors monitor people's heart rhythms long-term

Abbott's assert-iq offers the world's longest battery life† for an insertable cardiac monitor (icm) the latest addition to abbott's portfolio of connected health devices, the assert-iq icm offers long-term monitoring and remote programming to improve connectivity to patients the device provides continuous monitoring for abnormal heart rhythms while offering tools designed to help improve data management and workflow within a physician's practice abbott park, ill., may 18, 2023 /prnewswire/ -- abbott (nyse: abt) today announced its assert-iq™ insertable cardiac monitor (icm) has received u.s. food and drug administration (fda) clearance, giving physicians a new option for diagnostic evaluation and long-term monitoring of people experiencing irregular heartbeats.
ABT Ratings Summary
ABT Quant Ranking